A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Na ve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1

Brief description of study

If you have been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) you may qualify for this Phase 3 study. The main goal of this study is to evaluate the effectiveness of the addition of an investigational drug called enzastaurin to standard first line chemotherapy in patients with Diffuse Large B-Cell Lymphoma (DLBCL).


Clinical Study Identifier: s17-01110
ClinicalTrials.gov Identifier: NCT03263026
Principal Investigator: Catherine M Diefenbach
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.